deferiprone has been researched along with Inflammation in 9 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic." | 8.12 | Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022) |
| "Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic." | 4.12 | Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022) |
| " Here, we aimed to investigate the possible contribution of ferroptosis in the demyelinated optic nerve, and to explore the effectiveness of ferroptosis inhibitor, deferiprone (DFP), on the extent of demyelination, inflammation and axonal damage." | 4.12 | Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve. ( Foolad, F; Heibatollahi, M; Javan, M; Khajeh, K; Rayatpour, A, 2022) |
| "Deferiprone therapy was well tolerated and was associated with a reduced dentate and caudate nucleus iron content compared to placebo." | 2.84 | Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. ( Connelly, J; Crichton, RR; Dexter, DT; Kabba, C; Martin-Bastida, A; Newbould, R; Patel, MC; Piccini, P; Sharp, D; Spino, M; Tricta, F; Ward, RJ, 2017) |
| "Deferiprone has the potential to limit scar tissue formation and should be considered in future clinical applications." | 1.51 | Deferiprone has anti-inflammatory properties and reduces fibroblast migration in vitro. ( Gouzos, M; Ooi, ML; Psaltis, AJ; Ramezanpour, M; Smith, JLP; Vreugde, S; Wormald, PJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Di Paola, A | 1 |
| Tortora, C | 1 |
| Argenziano, M | 1 |
| Marrapodi, MM | 1 |
| Rossi, F | 1 |
| Sriwichaiin, S | 1 |
| Thiennimitr, P | 1 |
| Thonusin, C | 1 |
| Sarichai, P | 1 |
| Buddhasiri, S | 1 |
| Kumfu, S | 1 |
| Nawara, W | 1 |
| Kittichotirat, W | 1 |
| Fucharoen, S | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Rayatpour, A | 3 |
| Foolad, F | 3 |
| Heibatollahi, M | 3 |
| Khajeh, K | 3 |
| Javan, M | 3 |
| Lupu, M | 1 |
| Coada, CA | 1 |
| Tudor, DV | 1 |
| Baldea, I | 1 |
| Florea, A | 1 |
| Toma, VA | 1 |
| Lupsor, A | 1 |
| Moldovan, R | 1 |
| Decea, N | 1 |
| Filip, GA | 1 |
| An, HS | 1 |
| Yoo, JW | 1 |
| Jeong, JH | 1 |
| Heo, M | 1 |
| Hwang, SH | 1 |
| Jang, HM | 1 |
| Jeong, EA | 1 |
| Lee, J | 1 |
| Shin, HJ | 1 |
| Kim, KE | 1 |
| Shin, MC | 1 |
| Roh, GS | 1 |
| Martin-Bastida, A | 1 |
| Ward, RJ | 1 |
| Newbould, R | 1 |
| Piccini, P | 1 |
| Sharp, D | 1 |
| Kabba, C | 1 |
| Patel, MC | 1 |
| Spino, M | 1 |
| Connelly, J | 1 |
| Tricta, F | 1 |
| Crichton, RR | 1 |
| Dexter, DT | 1 |
| Ramezanpour, M | 1 |
| Smith, JLP | 1 |
| Ooi, ML | 1 |
| Gouzos, M | 1 |
| Psaltis, AJ | 1 |
| Wormald, PJ | 1 |
| Vreugde, S | 1 |
| Desroches, S | 1 |
| Biron, F | 1 |
| Berthon, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease[NCT01539837] | Phase 2 | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease, modify regional brain mineralization (iron concentration) as assessed with T2* MRI in PD patients in the dentate nucleus. In previous animal studies, Deferiprone treatment reduced dentate nucleus iron content, as assessed by MRI. An increase in the T2*MRI value represents an increase in mineralization. (NCT01539837)
Timeframe: 6 months
| Intervention | ms (Mean) |
|---|---|
| Placebo | 30.74 |
| Deferiprone 20mg | 30.59 |
| Deferiprone 30mg | 29.86 |
To assess whether there were any serious adverse events in 6-month treatment with Deferiprone. (NCT01539837)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Deferiprone 20mg | 0 |
| Deferiprone 30mg | 0 |
1 review available for deferiprone and Inflammation
| Article | Year |
|---|---|
Emerging Roles of the Iron Chelators in Inflammation.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agent | 2022 |
1 trial available for deferiprone and Inflammation
| Article | Year |
|---|---|
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
Topics: Aged; Brain; Brain Chemistry; Deferiprone; Double-Blind Method; Female; Humans; Inflammation; Iron; | 2017 |
7 other studies available for deferiprone and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study.
Topics: Animals; Cytokines; Deferiprone; Diet; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Iron; I | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve.
Topics: Animals; Deferiprone; Ferroptosis; Inflammation; Iron; Male; Mice; Mice, Inbred C57BL; Multiple Scle | 2022 |
Iron chelation alleviates multiple pathophysiological pathways in a rat model of cardiac pressure overload.
Topics: Animals; Deferiprone; Heart Failure, Systolic; Inflammation; Iron; Iron Chelating Agents; Iron Overl | 2023 |
Lipocalin-2 promotes acute lung inflammation and oxidative stress by enhancing macrophage iron accumulation.
Topics: Acute Lung Injury; Animals; Deferiprone; Inflammation; Iron; Lipocalin-2; Lipopolysaccharides; Lung; | 2023 |
Deferiprone has anti-inflammatory properties and reduces fibroblast migration in vitro.
Topics: Adult; Anti-Inflammatory Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen Type I | 2019 |
Aluminum speciation studies in biological fluids. Part 5. A quantitative investigation of A1(III) complex equilibria with desferrioxamine, 2,3-dihydroxybenzoic acid, Tiron, CP20 (L1), and CP94 under physiological conditions, and computer-aided assessment
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aluminum; Animals; Body Fluids; Chelating Ag | 1999 |